The frequency of neurodegenerative markers among long surviving human immunodeficiency virus (HIV)-infected individuals is unknown, therefore, the present study investigated the frequency of a-synuclein, b-amyloid, and HIVassociated brain pathology in the brains of older HIV-infected individuals. We examined the substantia nigra of 73 clinically well-characterized HIV-infected individuals aged 50 to 76 years from the National NeuroAIDS Tissue Consortium. We also examined the frontal and temporal cortical regions of a subset of 36 individuals. Neuritic a-synuclein expression was found in 16% (12/ 73) of the substantia nigra of the HIVcases and none of the older control cases (0/18). b-Amyloid deposits were prevalent and found in nearly all of the HIV cases (35/36). Despite these increases of degenerative pathology, HIV-associated brain pathology was present in only 10% of cases. Among older HIVadults, HIV-associated brain pathology does not appear elevated; however, the frequency of both a-synuclein and b-amyloid is higher than that found in older healthy persons. The increased prevalence of a-synuclein and b-amyloid in the brains of older HIV-infected individuals may predict an increased risk of developing neurodegenerative disease. Journal of NeuroVirology (2009) 15, 131Á138.
Introduction
Human immunodeficiency virus (HIV)-associated mortality has fallen significantly following the introduction of antiretroviral therapy (ARV) (Mocroft et al, 1998) . Consequently, individuals living with HIV are reaching older ages and may be at increased risk for developing other neurodegenerative diseases such as Alzheimer's disease. This seems especially likely as the brain is a target of HIV infection and results, pathologically, in synaptodendritic damage, neuronal loss, astrocytosis, and microgliosis, and, clinically, in the development of HIV-associated neurocognitive disorders (Everall et al, 1999; Masliah et al, 1997a; Bell et al, 1998; Moore et al, 2006) . A number of studies have examined the expression of human b-amyloid precursor protein (APP) as a marker of axonal degeneration and have noted an increase in expression in HIV disease and simian immunodeficiency virus Mankowksi et al, 2002) . In bigenic mice overexpressing both human APP and HIV envelope protein gp120, it was proposed that the APP may be protective against gliosis and synaptic loss (Masliah et al, 1997b) .
Green et al preformed immunocytochemistry for b-amyloid in 162 HIV-infected brains collected from 1983 to 2001 spanning both the pre-and post-HAART (highly active antiretroviral therapy) eras (Green et al, 2005) . They found evidence of bamyloid deposition in the frontal cortex in almost 50% of the cases and slightly less abundance in the hippocampus and basal ganglia. The b-amyloid was predominantly in the neuronal soma and axonal processes; there were some extracellular plaques and a few cases demonstrating deposition in blood vessels. There were no neurofibrillary tangles present, but there was a trend towards increasing bamyloid deposition in the post-HAART era.
In the current study, we have extended the investigation of markers of neurodegeneration to include a-synuclein. Lewy bodies, the morphological hallmark in the substantia nigra of Parkinson's disease are composed of filamentous a-synuclein, ubiquitin, neurofilament proteins, lipids, subunits of 26S proteasome, parkin, and synphilin-1 (Braak et al, 2000; Baba et al, 1998; Gai et al, 2000; Liao et al, 2004; Mankowski et al, 2002) . The function of asynuclein is still not clear; it is located at nerve terminals and is postulated to have a role in neurotransmitter release (Cabin et al, 2002; Murphy et al, 2000) . The aggregation of a-synuclein into fibrillary forms as found in Lewy bodies and Lewy dendrites are thought to be related to increased cellular oxidative stress (Hashimoto et al, 1999; Souza et al, 2000) . The presence of Lewy bodies is considered prodromal to Parkinson's disease and, therefore, the presence of significant amounts of asynuclein may indicate that affected individuals are at risk of future development of Parkinson's disease or other neurodegenerative disorders where a-synuclein is found to be increased (e.g., dementia with Lewy Bodies). Motor and information processing speed impairments are common among persons with HIV infection (Reger et al, 2002) and are consistent with some of the impairments observed in Parkinson's disease. In this study, we assessed for the presence of both a-synuclein and b-amyloid in the brains of older HIV-infected individuals with the hypothesis that these individuals are more likely to show pathological signs of other neurodegenerative disorders than would be expected for persons without HIV infection.
Results

Clinical data
The demographic characteristics of the HIV'sample are summarized in Table 1 . The median age of the HIV-infected cohort was 55 years, with the ages ranging from 50 to 76 years. The cohort was primarily male, Caucasian, with the primary mode of exposure being M2MS (male-to-male sexual encounter). Substance dependence was reported for a minority of individuals on whom these data were collected (18%; 7/38) and included alcohol, cocaine, and opiates. Documented CD4'cell count was available for 49 cases. Of these, 38 cases had a CD4 count below 200/mm 3 . Cerebrospinal fluid (CSF) viral load data were reported for 34 cases, the mean log of the group was 2.64 (standard deviation 0.92), but the data were somewhat skewed with a median log of 2.45 and interquartile range of 4.10 to 8.46. Basic ARV treatment information was available for 61 of the 73 cases examined. Of the subset with ARV data, 52 cases (85%) were on at least one ARV agent at their final visit prior to death. Premortem primary neurocognitive diagnoses were available for 49 of the 73 cases and the median interval between assessment and death was 71 days (interquartile range 25 to 150 days). Of these individuals, 5 had no impairment, 2 had subsyndromic neuropsychological impairment, 11 had possible or probable minor cognitive and motor disorder (MCMD), 11 had possible or probable HIV-associated dementia (HAD), 18 had neurocognitive impairment due to other causes (e.g., head injury, learning disability, substance abuse/dependence, stroke), and 2 had neurocognitive impairment of an uncertain cause. Thirty-eight individuals were recorded as having an episode of major depressive disorder (MDD) within the 2 years prior to death.
The 18 HIVÁ comparison cases used for this study had a median age of 56.0 and ranged from 51 to 67 years; 56% (10/18) were male. Control cases had no history of a neurodegenerative disease and causes of death included breast cancer, pulmonary thromboembolus, and various cardiac failures. The median postmortem interval for the controls was 23 hours.
Neuropathological findings
HIV-associated primary brain pathology was reported in 10% of the cases (7/73): 1 case of HIV encephalitis, 2 cases of HIV leukoencephalopathy, 3 cases of microglial nodules, and 1 case that had both HIV encephalitis and HIV leukoencephalopathy. No HIV-associated primary brain pathology was noted in the remaining 66 cases. Alzheimer type II gliosis was present in 15 cases (21%).
a-Synuclein staining was found in the substantia nigra of 12 out of 73 HIV'cases (16%), whereas there was no a-synuclein staining among our HIV seronegative control cases (0/18). There was no significant difference in the mean age of those cases without a-synuclein (5696 years) as compared to those cases exhibiting a-synuclein (5894 years). The most common form of a-synuclein staining was neuritic with both intracellular and dendritic staining ( Figure 1 ). Among the 12 cases, grade 1 asynuclein pathology was identified in 8 of the 12 cases (67%), grade 2 in 3 cases (25%), and grade 3 in 1 case (8%). We statistically compared the groups of cases with and without a-synuclein staining and found no significant differences in age, ethnicity/ race, mode of exposure, presence of HIV-associated primary brain pathology, neurocognitive performance (using global deficit score), substance abuse, plasma CD4'cell count, or CSF viral load.
A subset of 36 cases, supplied from University of California San Diego (UCSD) and Mount Sinai Medical Center, New York, provided tissue from the frontal, temporal, and hippocampal regions in addition to the substantia nigra tissue analyzed above. In these cases, we assessed for staining of both a-synuclein and b-amyloid. In this subseries, a-synuclein was observed in nine cases: five with a-synuclein in the substantia nigra only, two cases with a-synuclein in substantia nigra and the hippocampus, one case with a-synuclein in the substantia nigra, hippocampus, and frontal cortex, and one case with a-synuclein in frontal cortex only. bAmyloid staining was observed in 35 of the 36 cases in either the frontal, temporal, or hippocampal regions and this finding was corroborated with thioflavin S stain ( Figure 2 ). b-Amyloid staining was evaluated according to presence of intraneuronal staining, extraneuronal amyloid plaques, or both. Intraneuronal staining was the most frequent form of expression and no extraneuronal amyloid plaques were observed. In the frontal cortex, there were 32 cases with intraneuronal staining and 2 with intraneuronal staining and vessel wall deposits. In the temporal cortex, there were 30 cases with intraneuronal staining and 2 with intraneuronal staining and vessel wall deposits, whereas in the hippocampus, there were 31 cases with intraneuronal staining and 1 with intraneuronal staining and vessel wall deposits. There was no statistically significant relationship between the presence of a-synuclein and b-amyloid. Of the 36 cases and considering all available brain regions (including substantia nigra), only 1 had neither marker, 26 had just b-amyloid, and 9 had both a-synuclein and b-amyloid.
No significant association was found between the severity of neurocognitive diagnosis and presence of a-synuclein. We were unable to assess the relationship between neurocognitive diagnosis and b-amyloid staining given the lack of variability in the presence of b-amyloid (i.e., 35 of 36 cases had b-amyloid).
Discussion
We assessed the frequency of primary HIV-associated brain pathology, a-synuclein in the substantia Increased frequency of a-synuclein in HIV nigra, and b-amyloid, corroborated with thioflavin S, in cortical regions in a cohort of HIV-infected individuals aged 50 years and above. The substantia nigra was available in 73 cases and cortical regions in a subsample of 36 cases. In the substantia nigra, we observed that 12 out of 73 cases exhibited asynuclein staining, which was neuritic, representing a frequency of 16%. In eight of these cases, the neuritic staining by a-synuclein covered at most 25% of the tissue. By comparison, none of our HIV seronegative cases displayed a-synuclein. Furthermore, in a previous study of Lewy body staining using a-synuclein in progressive supranuclear palsy (PSP), there was assessment of 98 control subjects, aged 60 to 100 years and consisting of 48 males and 50 females; Lewy bodies were only noted in 9 controls, representing a frequency of 9% (Tsuboi et al, 2001 ). Although our sample was younger (median age 55 years and 75% less than 60 years) and not directly comparable, it is interesting that our HIVinfected cohort has almost double the frequency of cases with a-synuclein staining as compared to the control cases in the PSP study. However, we are hesitant to draw strong conclusions from this finding given the inability to compare these percentages statistically.
In a subset of 36 cases, tissue was available from the frontal and temporal cortex and hippocampus. In this subset, 4 of 36 cases had evidence of asynuclein in cortical structures (hippocampus or frontal cortex). These findings were mostly in cases where a-synuclein staining was also observed in the substantia nigra; a single case had a-synuclein present in the frontal cortex but absent in the substantia nigra. The cortical regions were also assessed for the presence of b-amyloid and this was observed in 35 of the cases. This represents a frequency of 97%, which exceeds previously observed findings. For example, Green et al (2005) assessed 162 AIDS autopsies collected between 1983 and 2001; only a few of whom had ARVs and the cohort had a mean age of 41.5 years. Similarly, Anthony et al (2006) assessed 9 HIV-infected and 18 acquired immunodeficiency syndrome (AIDS) autopsies, all of whom received ARV therapy and had a mean age 40 years. Both of these studies observed b-amyloid deposition in just under half of their respective series. In the Green et al series, the bamyloid was generally restricted to plaques, whereas in the study by Anthony et al, the staining was predominantly in the somal and axonal processes. In our current study, we found no staining suggesting extracellular deposition of b-amyloid; it was either intraneuronal or in vessel walls. Green et al also reported that the amount of b-amyloid staining appeared to be increasing in the era following the introduction of ARV therapy. This observation, together with our cohort being older, may explain the even higher frequency of b-amyloid that we noted as our brains were only collected from the antiretroviral era of 1999 to 2005.
Interestingly, there was no relationship between the presence of either a-synuclein or b-amyloid staining and the development of either HIV-associated cognitive impairment or MDD. However, it is possible that as the 'load' of these neurodegenerative markers increases, the affected individuals, if they survive, may be at risk of developing dementia of numerous types, including Parkinson's and Alzheimer's diseases. With regard to b-amyloid, previous reports have shown that cytokines such as interleukin-1, tumor necrosis factor-a and interferon-g can stimulate the activity of g-secretase, which cleaves amyloid precursor protein into b-amyloid (Liao et al, 2004) . Furthermore, the HIV regulatory protein tat can inhibit the activity of the b-amyloidÁ degrading protein neprilysin (Rempel et al, 2005; Daily et al, 2006) . To date, the processing of asynuclein is still being clarified, but its deposition may result from interaction with, and impairment of, proteasome processing (Snyder et al, 2003) . HIV infection may exacerbate the process of a-synuclein deposition by at least two independent processes. First, the HIV protein tat can bind to and inhibit members of the proteasome (Apcher et al, 2003) ; and, second, protease inhibitors are now recognized to also inhibit proteasomal machinery (Apcher et al, 2003; Piccinini et al, 2005) . Furthermore, we did find evidence of actual Lewy bodies in the substantia nigra of our HIV'cohort, suggesting that a-synuclein has aggregated sufficiently to create abnormal pathological bodies in this region. It is possible that HIV-and ARV-associated proteasomal dysfunction, together with prolonged survival, may result in an increased risk of other neurodegenerative markers. Thus, both the improved outcome and components of the treatment regimen that have enhanced survival may unwittingly contribute to an increased risk of other common neurodegenerative diseases such as Alzheimer's and Parkinson's diseases.
Although the results of this study suggest that there may be increased presence of pathological processes in older persons with HIV infection, we acknowledge that there are limitations to the present study. First, the number of HIV seronegative control cases is rather small (n 018); yet, the complete absence of a-synuclein in the substantia nigra of these cases argues for the pathological nature of a-synuclein in HIV. Second, we recognize that the lack of detailed ARV data is a limitation in terms of drawing strong conclusions about the impact of such medications on the increased presence of a-synuclein and b-amyloid in these older HIV-infected cases; however, it is a reasonable speculation that ARVs may possibly contribute to the observed pathology.
In sum, the greater than expected prevalence of a-synuclein and b-amyloid in the brains of older HIV-infected persons with autopsy suggests that these persons may be at greater risk for neurodegenerative diseases common among older adults. Clarification of the mechanisms that result in the increased frequency of markers of neurodegenerative disorders in surviving older HIV-infected individuals may become the future targets of therapeutic development to prevent the occurrence of further causes of cognitive impairment.
Methods
Autopsy cases
We examined tissue from the substantia nigra of 73 HIV-infected autopsy cases age 50 or older. Tissue was provided by the National NeuroAIDS Tissue Consortium (NNTC), which has four sites (University of Texas, Galveston; University of California, San Diego [UCSD]; University of California, Los Angles; and Mount Sinai Medical Center, New York). Tissue from frontal cortex, hippocampus, and temporal cortex was also available for the 36 cases provided by University of California, San Diego, and Mount Sinai Medical Center, New York. The NNTC was established in 1998; therefore, all of the cases used in this study are from the post-HAART era.
In addition, we also analyzed a-synuclein presence in the substantia nigra among 18 older HIV seronegative cases. These control cases were obtained through the UCSD Medical Center autopsy service and/or were control cases from the California NeuroAIDS Tissue Network (CNTN) at UCSD. All cases were 50 years old or older and were free of neurodegenerative conditions. Demographic, clinical, and pathological data Demographic, clinical, and pathological details were made available through the NNTC National Coordinating Office. Patient enrollment, data collection, tissue sampling protocols, and diagnostic criteria have been described previously (Morgello et al, 2001) . Data included age, gender, ethnicity (Hispanic/Latino or not), race (white, black/AfricanAmerican, Asian, native Alaskan/American Indian, native Hawaiian/Pacific islander) and mode of exposure to HIV. The mode of exposure was identified as male-to-male sexual encounter (M2MS), intravenous drug users (IVD), heterosexual transmission, contaminated blood product recipient, and other and unknown mode of transmission.
Clinical evaluation encompassed the DSM-IV criteria for neurobehavioral, psychiatric disorders, and drug abuse. The methods of neurocognitive evaluation have been described previously and included a comprehensive neuropsychological test battery assessing learning, memory, attention, information processing, abstraction, verbal fluency, and motor skills . Primary neurocognitive diagnoses were assigned using results from the comprehensive neuropsychological battery. Overall level of neuropsychological impairment was determined using a global deficit score (Carey et al, 2004) . Participants were categorized according to the absence of neurocognitive disorder, non syndromic disorder, minor cognitive motor disorder (MCMD), HIV-associated dementia (HAD), cytomegalovirus encephalitis, impairment due to factors other than HIV, and primary neurocognitive disorder of unknown cause. The neuropsychological assessment also included screening for the presence of major depressive disorder; this was determined either by the Composite International Diagnostic Interview or the Psychiatric Research Interview for Substance and Mental Disorders. Laboratory markers included the most recent total CD4 count and cerebrospinal fluid (CSF) viral load prior to death. Data on whether patients had received ARVs includes the regimen being administered during the interval prior to, and at the time of, the last study visit.
Data were provided by the NNTC as to whether cases did or did not have HIV-associated brain pathology as determined by standardized procedures across the four NNTC sites (Morgello et al, 1991) . HIV-associated primary brain pathology was defined as presence of one or more of the following postmortem diagnoses: HIV encephalitis (HIVE), leukoencephalopathy, and/or microglial nodules as defined according to the 1991 consensus report (Budka et al, 1991) .
Immunohistochemistry (IHC) and other neuropathological stains All immunohistochemistry was conducted at the CNTN. Using 10 mm thick paraffin-waxÁembedded tissue sections, the following antibodies were used in our IHC protocols: rabbit polyclonal anti-a-synuclein (Chemicon International, CA) and mouse monoclonal b-amyloid 4G8 antibodies (Signet Laboratories, MA). To detect a-synuclein expression, paraffin-waxed sections were rehydrated through graded ethanol concentrations and the endogenous peroxidase was inactivated by 0.3% H 2 O 2 solution. The rabbit anti-a-synuclein antibody (1:1000 dilution) diluted in background reducing component (DakoCytomation, CA) was applied for 15 minutes at room temperature and the protein was detected using streptavidin-biotin link LSAB2 system (DakoCytomation) and 3,3'-diaminobenzidine substrate for peroxidase (Vector Laboratories, CA). For b-amyloid expression, brain tissue sections were pretreated with 88% formic acid for 20 minutes to enhance the detection and then treated with 0.3% H 2 O 2 solution, followed by sodium citrate buffer in microwave for 10 minutes. To block the nonspecific lipofuscin autofluorescence, sections were treated with Sudan Black solution from Chemicon for 10 minutes prior to the labeling for b-amyloid per the Increased frequency of a-synuclein in HIV manufactures instructions. Tissue was exposed to the primary antibody (1:2000) for 24 h at 48C. All sections were counterstained with hematoxylin and analyzed using a light microscope. For quality control purposes, known positive-and negativecontrol sections were included in each IHC run. The b-amyloid immunostaining was corroborated with thioflavin S staining. Sections were rehydrated through graded ethanol and placed in 1% thioflavin S (Sigma, St. Louis, MO) for 7 minutes. The thioflavin S reaction was analyzed by fluorescent microscopy.
Semiquantitative grading of a-synuclein expression The degree of a-synuclein expression was graded semi-quantitatively as: grade 0 (no signal), grade 1 (a-synuclein neuritic staining involving 525% of the tissue), grade 2 (a-synuclein neuritic staining involving more than 25% of the tissue), and grade 3 (neuritic staining associated with intraneuronal Lewy bodies). The rating was made by assessing several microscopic fields and consensus by two neuropathologists
Statistical analysis
Analyses were conducted with JMP 6.0 and SAS 9.1 software (SAS Institute, NC). When appropriate parametric assumptions were met, linear regression and analysis of variance (ANOVA) were employed to examine predictors of continuous response variables. x 2 and Fisher's exact tests were used for contingency analysis. Log 10 and square root transformations were applied to viral loads and CD4 counts, respectively, and the transformed variables were analyzed employing the Wilcoxon rank-sum method. Each subset of cases with and without pathology detected by IHC was separately analyzed with regards to clinical and pathological findings.
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